27631-28-3

Usage

Heterocyclic amine

It contains a basic nitrogen atom in its structure, which can form hydrogen bonds and participate in various chemical reactions.

Fused imidazole and quinazoline ring system

The imidazole and quinazoline rings are fused together, creating a complex and stable structure.

Potential applications in medicinal chemistry

Due to its unique structure and properties, 2,3-DIHYDRO-IMIDAZO[1,2-C]QUINAZOLIN-5-YLAMINE may have potential uses in the development of new drugs and therapies.

Drug development

The compound's structural features and potential biological activities make it a promising candidate for further research in the pharmaceutical industry.

Therapeutic agent

Further studies may reveal the potential of 2,3-Dihydro-imidazo[1,2-c]quinazolin-5-ylamine as a treatment for various diseases and conditions.

Valuable target for pharmaceutical chemistry research

The compound's potential applications and unique structure make it an important subject for further investigation in the field of pharmaceutical chemistry.

Upstream product

• 506-68-3 bromocyane 
• 28637-61-8 2-(2-aminophenyl)-4,5-dihydro-1H-imidazole 
• 1885-29-6 anthranilic acid nitrile 
• 552-89-6 2-nitro-benzaldehyde 
• 1361234-34-5 methyl N-cyano-2-nitrobenzenecarboximidoate 

Downstream Products

• 32725-30-7 2,3-dihydroimidazo<2,1-b>quinazolin-5(1H)-one 
• 677341-06-9 C₁₇H₂₀N₄O 
• 677339-76-3 C₁₇H₁₄N₄O 

Relevant academic research and scientific papers

Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)

The phosphoinositide 3-kinase (PI3K) pathway is aberrantly activated in many disease states, including tumor cells, either by growth factor receptor tyrosine kinases or by the genetic mutation and amplification of key pathway components. A variety of PI3K isoforms play differential roles in cancers. As such, the development of PI3K inhibitors from novel compound classes should lead to differential pharmacological and pharmacokinetic profiles and allow exploration in various indications, combinations, and dosing regimens. A screening effort aimed at the identification of PI3Kγ inhibitors for the treatment of inflammatory diseases led to the discovery of the novel 2,3-dihydroimidazo[1,2-c]quinazoline class of PI3K inhibitors. A subsequent lead optimization program targeting cancer therapy focused on inhibition of PI3Kα and PI3Kβ. Herein, initial structure–activity relationship findings for this class and the optimization that led to the identification of copanlisib (BAY 80-6946) as a clinical candidate for the treatment of solid and hematological tumors are described.

Synthesis of 2,4-diaminoquinazolines and tricyclic quinazolines by cascade reductive cyclization of methyl N -cyano-2-nitrobenzimidates

An efficient route to N4-substituted 2,4-diaminoquinazolines has been developed by employing tandem condensation of cyanoimidate-amine and reductive cyclization in iron-HCl system. This method is tolerant of a following intramolecular N-alkylation and produces two fused heterocycles in a one-pot procedure. This protocol is a facile two-step synthesis of tricyclic quinazolines, which is effected by potent cyanoimidation and tandem reductive cyclization from 2-nitrobenzaldehydes. Moreover, the forming process of tricyclic quinazolines has been investigated from the ring-opening/ring-closing cascade point of view. It is found that the preparation of tricyclic quinazolinones in good yields relies on the selective hydrolysis of tricyclic quinazolines in base or acid system.